David Pelizzon Sells 22,500 Shares of OrthoPediatrics (NASDAQ:KIDS) Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) Director David Pelizzon sold 22,500 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $23.35, for a total transaction of $525,375.00. Following the completion of the sale, the director owned 6,504,133 shares in the company, valued at $151,871,505.55. This represents a 0.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

OrthoPediatrics Stock Down 0.8%

KIDS stock traded down $0.18 during mid-day trading on Friday, reaching $22.41. 129,506 shares of the company traded hands, compared to its average volume of 173,525. The stock has a market cap of $585.13 million, a price-to-earnings ratio of -13.34 and a beta of 0.99. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28. OrthoPediatrics Corp. has a fifty-two week low of $14.42 and a fifty-two week high of $26.74. The firm’s 50 day moving average price is $21.74 and its 200 day moving average price is $18.84.

OrthoPediatrics (NASDAQ:KIDS) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. The business had revenue of $70.51 million during the quarter, compared to analyst estimates of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. As a group, equities research analysts predict that OrthoPediatrics Corp. will post -1.14 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have commented on KIDS shares. TD Cowen reiterated a “buy” rating on shares of OrthoPediatrics in a research note on Monday, June 15th. Weiss Ratings raised OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 5th. Needham & Company LLC increased their price target on OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. BTIG Research lifted their price target on OrthoPediatrics from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Thursday, August 20th. Finally, Truist Financial set a $22.00 price objective on OrthoPediatrics in a research report on Wednesday, August 5th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, OrthoPediatrics has an average rating of “Moderate Buy” and an average price target of $26.44.

Institutional Trading of OrthoPediatrics

Several hedge funds have recently added to or reduced their stakes in KIDS. Russell Investments Group Ltd. grew its position in shares of OrthoPediatrics by 433.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock valued at $26,000 after acquiring an additional 1,139 shares during the period. Legal & General Group Plc bought a new stake in shares of OrthoPediatrics in the 2nd quarter worth approximately $34,000. Northwestern Mutual Wealth Management Co. lifted its stake in OrthoPediatrics by 5,226.5% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock valued at $46,000 after purchasing an additional 2,561 shares during the last quarter. Caption Management LLC purchased a new stake in OrthoPediatrics in the 3rd quarter worth about $54,000. Finally, BNP Paribas Financial Markets raised its position in shares of OrthoPediatrics by 60.2% in the third quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock valued at $61,000 after purchasing an additional 1,235 shares during the period. Institutional investors own 69.05% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.